State Drug Administration approves application for import registration of recombinant shingles vaccine (Singrix)
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the NationalDrug(http://to approve the approval of the recombinant shingles vaccine (Singrix) import registration application for the prevention of shingles in adults 50 years and olderAboutShingrix uses DNA recombination technology to express chickenpox shingle virus glycoprotein E in Chinese hamster ovary cells, which is cultured, harvested, purified, freeze-dried and made to have better protective effect on shinglesThe main population of the vaccine is also in this range because the main population with shingles in the country is middle-aged and elderly aged 50-70Common adverse reactions to vaccines include pain, redness, swelling, and myalgia, fatigue, headache, fever and gastrointestinal symptomsEven those who have had shingles or have been vaccinated against Zostavax can be vaccinated, the medical friend warnedHowever, pregnant, lactating women and chickenpox sourcetested(http://negative is not suitable for injection of Shingrix
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
